These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27329786)

  • 1. Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.
    Lim J; Kelley EH; Methot JL; Zhou H; Petrocchi A; Chen H; Hill SE; Hinton MC; Hruza A; Jung JO; Maclean JK; Mansueto M; Naumov GN; Philippar U; Raut S; Spacciapoli P; Sun D; Siliphaivanh P
    J Med Chem; 2016 Jul; 59(13):6501-11. PubMed ID: 27329786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors.
    Lu H; Tu W; Fei H; Xu G; Hu Q; Zhang L; Lin B; Yuan J; Yin J; Gong A; Wan M; Wang D; Zhu X; Feng J; Wang Q; Sun P
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2555-9. PubMed ID: 24755426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.
    Blake JF; Burkard M; Chan J; Chen H; Chou KJ; Diaz D; Dudley DA; Gaudino JJ; Gould SE; Grina J; Hunsaker T; Liu L; Martinson M; Moreno D; Mueller L; Orr C; Pacheco P; Qin A; Rasor K; Ren L; Robarge K; Shahidi-Latham S; Stults J; Sullivan F; Wang W; Yin J; Zhou A; Belvin M; Merchant M; Moffat J; Schwarz JB
    J Med Chem; 2016 Jun; 59(12):5650-60. PubMed ID: 27227380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
    Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
    Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
    Yang W; Chen Y; Zhou X; Gu Y; Qian W; Zhang F; Han W; Lu T; Tang W
    Eur J Med Chem; 2015 Jan; 89():581-96. PubMed ID: 25462267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting Therapeutic Resistance to ERK Inhibition.
    Jha S; Morris EJ; Hruza A; Mansueto MS; Schroeder GK; Arbanas J; McMasters D; Restaino CR; Dayananth P; Black S; Elsen NL; Mannarino A; Cooper A; Fawell S; Zawel L; Jayaraman L; Samatar AA
    Mol Cancer Ther; 2016 Apr; 15(4):548-59. PubMed ID: 26832798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
    Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
    Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.
    Defaux J; Antoine M; Logé C; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3748-52. PubMed ID: 25022204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
    Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New diarylamides and diarylureas possessing 8-amino(acetamido)quinoline scaffold: synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition, and in silico studies.
    Koh EJ; El-Gamal MI; Oh CH; Lee SH; Sim T; Kim G; Choi HS; Hong JH; Lee SG; Yoo KH
    Eur J Med Chem; 2013; 70():10-21. PubMed ID: 24128410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
    Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
    Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.
    Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Bräse S; Ibrahim MAA; Nieger M; Garvalov BK; Dalby KN; Kaoud TS
    Bioorg Chem; 2019 Feb; 82():290-305. PubMed ID: 30396063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
    Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of nitroaryl urea derivatives with antiproliferative properties.
    Wróbel TM; Kiełbus M; Kaczor AA; Kryštof V; Karczmarzyk Z; Wysocki W; Fruziński A; Król SK; Grabarska A; Stepulak A; Matosiuk D
    J Enzyme Inhib Med Chem; 2016 Aug; 31(4):608-18. PubMed ID: 26114307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer.
    Liu B; Fu L; Zhang C; Zhang L; Zhang Y; Ouyang L; He G; Huang J
    Oncotarget; 2015 Mar; 6(9):6762-75. PubMed ID: 25742792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.
    Blake JF; Gaudino JJ; De Meese J; Mohr P; Chicarelli M; Tian H; Garrey R; Thomas A; Siedem CS; Welch MB; Kolakowski G; Kaus R; Burkard M; Martinson M; Chen H; Dean B; Dudley DA; Gould SE; Pacheco P; Shahidi-Latham S; Wang W; West K; Yin J; Moffat J; Schwarz JB
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2635-9. PubMed ID: 24813737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).
    Ugolini A; Kenigsberg M; Rak A; Vallée F; Houtmann J; Lowinski M; Capdevila C; Khider J; Albert E; Martinet N; Nemecek C; Grapinet S; Bacqué E; Roesner M; Delaisi C; Calvet L; Bonche F; Semiond D; Egile C; Goulaouic H; Schio L
    J Med Chem; 2016 Aug; 59(15):7066-74. PubMed ID: 27355974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
    Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
    Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel N
    Qi B; Yang Y; He H; Yue X; Zhou Y; Zhou X; Chen Y; Liu M; Zhang A; Wei F
    Eur J Med Chem; 2018 Feb; 146():368-380. PubMed ID: 29407963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.